Global Drugs for Immunotherapy Market

The cellular immunotherapy market consists of revenues generated by the companies engaged in developing, manufacturing, and sales of cellular immunotherapy drugs. Cellular immunotherapy is also known as adoptive cell therapy, a form of treatment that utilizes the cells of the immune system to eliminate diseases including non-Hodgkin lymphoma, cancer, and acute lymphoblastic leukemia. The main therapies of cellular immunotherapy are tumor-infiltrating lymphocyte (TIL) therapy, engineered T cell receptor (TCR) therapy, chimeric antigen receptor (CAR) T cell therapy, and natural killer (NK) cell therapy. Tumor-infiltrating lymphocyte (TIL) therapy is a type of adoptive cellular therapy that involves extracting infiltrated lymphocytes from tumors, culturing and amplifying them in vitro, and then infusing them back into patients to treat them. The various primary indication includes b-cell malignancies, prostate cancer, renal cell carcinoma, liver cancer, non-Hodgkin lymphoma, and others and is used for the treatment of prostate cancer, breast cancer, skin cancer, ovarian cancer, brain tumour, lung cancer, and others. The cellular immunotherapy market research report is one of a series of new reports from The Business Research Company that provides cellular immunotherapy market statistics, including cellular immunotherapy industry global market size, regional shares, competitors with a cellular immunotherapy market share, detailed cellular immunotherapy market segments, market trends and opportunities, and any further data you may need to thrive in the cellular immunotherapy industry. This cellular immunotherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global cellular immunotherapy market is expected to grow from $3.68 billion in 2021 to $4.30 billion in 2022 at a compound annual growth rate (CAGR) of 17%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The cellular immunotherapy market is expected to reach $7.60 billion in 2026 at a CAGR of 15.3%. Increasing research and successful clinical trials in cellular immunotherapy are expected to drive the growth of the cellular immunotherapy market over the forecast period. Companies are focusing on developing new cellular immunotherapies for treating different diseases. The rapid growth in the development of cellular immunotherapy in clinical and preclinical stages in 2020 as compared to that in 2019 is projected to expand the landscape of cellular immunotherapy. Subsequently, generating higher revenues for the cellular immunotherapy market. The high cost of cellular immunotherapies is anticipated to hinder cellular immunotherapy’s market growth. CAR-T therapy is a type of cellular immunotherapy and only two have been approved in the USA. The price of Yescarta and Kymriah is more than $350,000 per treatment in the USA, which is highly unaffordable for a majority of the patients, especially with low income. The high cost of cellular immunotherapies discourages patients to opt for this drug, thereby, impacting the demand and the market negatively. Companies in the cellular immunotherapy market are focusing on developing off-the-shelf allogeneic therapies for new and improved cancer treatment. Off-the-shelf allogeneic therapies are produced from the cells of donors instead of the patient cells as in the case of autologous therapy. Their non-customized nature provides advantages such as cost-effectiveness, large scale, fast, and quality control production. For instance, in November 2019, Precision Biosciences, Inc., a biotechnology company, created a new generation of allogeneic CAR-T therapy and is conducting an ongoing trial of this therapy by creating its first off-the-shelf allogeneic CAR-T therapy candidate known as PBCAR0191. This is in collaboration with Servier, an international pharmaceutical company, and is mainly for patients in need of advanced cancer treatment options. Additionally, in August 2020, Acepodia, a US-based next-generation cell immuno-technology company, initiated a phase 1 clinical trial for evaluating ACE1702 an allogeneic, off-the-shelf NK cell therapy for the treatment of solid tumors. In April 2020, resTORbio, Inc., a US-based biopharmaceutical company specializing in the development and commercialization of drugs used for the treatment of aging-related diseases, merged with Adicet Bio, Inc., a biopharmaceutical company, for an undisclosed amount. Both the companies continue their operations as ‘Adicet Bio’. This merger is expected to help the companies in advancing allogeneic gamma-delta CAR-T cell therapy technology. Adicet Bio, Inc. is a US-based company specializing in the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications. Major players in the cellular immunotherapy market are Novartis AG, Gilead Sciences Inc. (Kite Pharma), Apac Biotech, Dendreon Pharmaceuticals LLC, JW CreaGene Co. Ltd, Green Cross Corp (GC Pharma), AstraZeneca, Bristol-Myers Squibb, Pfizer Inc. and Roche. The regions covered in the cellular immunotherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cellular immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA The global cellular immunotherapy market is segmented - 1) By Therapy: Tumour-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy 2) By Primary Indication: B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Others 3) By Application: Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumour, Lung Cancer, Others

The colorectal cancer drugs market consists of the sale of colorectal cancer drugs. Colorectal cancer (CRC) or bowel cancer, is cancer affecting the large intestine and the rectum. They are also named, colon tumors or rectal cancer depending upon where they begin. The main types of colorectal cancer drugs are vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, and programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factors (VEGF) are drugs that block VEGF and VEGFR activity. The various classes of drugs include immunotherapy, chemotherapy, and others that are distributed by hospitals pharmacies, retail pharmacies, and others. The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global colorectal cancer drugs market grew from $12.75 billion in 2021 to $13.71 billion in 2022 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The colorectal cancer drugs market is expected to grow to $16.01 billion in 2026 at a CAGR of 3.9%. The number of colorectal cancer worldwide has been increasing. According to the American Cancer Society (ACS), there were around 101,420 new cases of colon cancer and around 44,180 new cases of rectal cancer registered in the USA in 2019. The diagnosed incident cases of colorectal cancer are expected to increase by 27.3% to 672,400 cases by 2037. The reason for this increase can be attributed to factors such as a low-fiber diet, obesity, and consumption of alcohol and tobacco amongst others. The increase in the number of colorectal cases will add to the overall size of the global colorectal cancer drugs market. The increasing use of biologics and targeted therapies restrains the bladder cancer drugs market. Biologic therapy uses a body’s immune system to fight cancer rather than chemical drugs which reduces the body’s immune power. Targeted therapies block the growth and spreading of colorectal cancer even in stage IV where chemical drugs are ineffective. For example, some targeted therapies that have been approved to treat colorectal cancer include bevacizumab, cetuximab, and panitumumab. The advantages of biological drugs and targeted therapies over conventional chemical drugs might negatively influence the market. Targeted therapies have already begun to extend the lifespan of metastatic Colorectal cancer patients compared with chemotherapy-only therapy. Target therapy includes hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing the toxicity to off-target cells. Opdivo and Keytruda are examples of targeted therapies. The colorectal cancer industry is governed by a regulatory framework laid down by agencies such as the US Food and Administration Agency (FDA), the European Medicines Agency (EMA), the American Society of Clinical Oncology (ASCO), and others. For instance, the FDA's recommendation for the colorectal cancer drugs industry in the form of guidelines is mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from A to me. The sub-part E deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as colorectal cancer. It also includes guidelines for the monitoring and evaluation of clinical trials of colorectal cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. In April 2019, Bristol-Myers Squibb Company, an American pharmaceutical company got the approval to acquire Celgene corporation for $74 billion. The transaction is expected to create a leading specialty company that would address the needs of patients with cancer, inflammatory and immunologic disease, and cardiovascular disease through high-value innovative medicines and leading scientific capabilities. Celgene Corporation, a company that develops medicines for cancer and inflammatory disorders, was founded in 1996 and has its headquarters in the USA. Major players in the colorectal cancer drugs market are Merck & Co. Inc, Roche, Sanofi, Amgen, Pfizer Inc., Abbott Laboratories, Taiho Pharma, Novartis, GlaxoSmithKline, Onyx, TAKEDA PHARMACEUTICALS, Bristol-Myers Squib, Sumitomo Dainippon Pharma, Array BioPharma, Eli Lilly, RANDOX LABORATORIES, Suzhou Zelgen Biopharmaceuticals, Beckman Coulter Inc, Regeneron, EDP Biotech, Genomic Tree, Metabiomics Corporation, SIEMENS HEALTHCARE, Suzhou Zelgen Biopharmaceuticals, Sumitomo Dainippon Pharma and EPIGENOMICS. North America was the largest region in the colorectal cancer drugs market in 2021. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global colorectal cancer drugs market is segmented - 1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators 2) By Distribution Channels: Hospitals Pharmacies, Retail Pharmacies, Others 3) By Class: Immunotherapy, Chemotherapy, Others

The oncology devices market consists of sales of oncology devices and related services provided by the manufacturer of oncology devices. Oncology is a branch of science that investigates cancer cells. Oncology devices are medical devices used in the diagnosis, management, and treatment of cancer, including breast cancer, lung cancer, pancreatic cancer, blood cancer, ovarian cancer, gastric cancer, skin cancer, kidney cancer, and brain tumour. The main device types of oncology devices are brachytherapy devices and endoscopic devices. Endoscopic devices are medical devices used in the diagnosis, management, and treatment of cancer. It is utilized to look internally at a body cavity or organ. These are used in various therapies such as chemotherapy, hormone therapy, biotherapy/immunotherapy, and radiation therapy that are used by various end-users such as hospitals, cancer research institutes, and others. The oncology devices market research report is one of a series of new reports from The Business Research Company that provides oncology devices market statistics, including oncology devices industry global market size, regional shares, competitors with a oncology devices market share, detailed oncology devices market segments, market trends and opportunities, and any further data you may need to thrive in the oncology devices industry. This oncology devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global oncology devices market is expected to grow from $91.47 billion in 2021 to $107.81 billion in 2022 at a compound annual growth rate (CAGR) of 17.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The oncology devices market is expected to grow to $216.35 billion in 2026 at a CAGR of 19%. A growing number of cancer cases across the globe is anticipated to boost the demand for the oncology devices market. Cancer is a major health problem across the globe and is the second leading cause of death in the USA. The increasing incidence of cancer is contributing to the surge in demand for oncology devices to treat cancer patients. The four most common types of cancer globally are prostate, lung, bowel, and female breast cancer, accounting for 43% of all new cancer cases. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. Therefore, the rise in cancer incidence is anticipated to boost the demand for the oncology drugs market. The low per capita expenditure on healthcare in developing countries is anticipated to limit the growth of the oncology devices market. The per capita expenditure on healthcare is very low in emerging economies such as China, India, and Indonesia as compared to developed nations. For instance, in 2020, according to India's total per capita, government spending on healthcare has almost doubled from ?1,008 per person in the year 15 to ?1,944 in the year 2020 but is still low. The total expenditure by the Centre and states for the year 2020 was ?2.6 trillion, or 1.29% of GDP, as well as establishment expenditure comprising salaries, gross budgetary help to different institutions and hospitals, and transfers to states centrally sponsored schemes like Ayushman Bharat. Major companies in the market, research institutes, and governments are continuously focusing on developing new devices to treat cancer patients. For instance, AIROS Medical Inc., a medical technology company based in the USA, launched AIROS 6 sequential compression therapy device and garment system to treat breast cancer patients. The advanced technology expanded upper extremity post-mastectomy treatment options for patients with lymphedema. In June 2019, Varian Medical Systems, a US-based company that specializes in radiation oncology treatment and software, announced the acquisition of Endocare, Inc., and Alicon for $185 million. With the acquisition of Endocare Inc. and Alicon, Varian Medical Systems plans to expand its cancer care solutions. Endocare, Inc. is a US-based company that offers systems and disposables for cryoablation and microwave ablation. Alicon is a company based in China and engaged in making embolic therapy for treating liver cancer. Major players in the oncology devices market are Eckert & Ziegler BEBIG, Oncura Inc, GE Healthcare, Medtronic plc, Varian Medical Systems Inc, Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, and IBA Group. North America was the largest region in the oncology devices market in 2021. Asia Pacific was the second largest region in the oncology devices market. The regions covered in the oncology devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the oncology devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global oncology devices market is segmented - 1) By Device Type: Brachytherapy Devices, Endoscopic Devices 2) By Therapy: Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, Radition Therapy 3) By End User: Hospitals , Cancer Research Institutes, Other End Users

Oncology Drugs Definition

The oncology drugs market consists of sales of oncology drugs and related services by entities (organizations, sole traders and partnerships) that produce oncology drugs to diagnose and treat all types of cancers. This industry includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating pancreatic cancer, breast cancer, ovarian cancer, gastric cancer, kidney cancer, brain tumor, and other cancer types. The pharmaceutical industry develops drugs to diagnose, treat or prevent diseases. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing. Oncology drug manufacturers produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

The prostate cancer drugs market consists of sales of various drugs used for the prevention and treatment of prostate cancer. Prostate cancer is one of the most common types of cancer caused due to uncontrollable development of cells in the prostate gland in men that produces the seminal fluid that nourishes and transports sperm. Some of the possible treatments for prostate cancer include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy. The different types of prostate cancer drugs are hormone-sensitive prostate cancer and hormone-refractory prostate cancer. Hormone-refractory prostate cancer (HRPC) is a kind of prostate cancer that no longer responds to hormone therapy, even newer treatments. The different types of therapies include hormonal therapy, chemotherapy, immunotherapy, and targeted therapy and involve various sectors such as hospitals, clinics, and others. The prostate cancer drugs market research report is one of a series of new reports from The Business Research Company that provides prostate cancer drugs market statistics, including prostate cancer drugs industry global market size, regional shares, competitors with a prostate cancer drugs market share, detailed prostate cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the prostate cancer drugs industry. This prostate cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global prostate cancer drugs market grew from $16.07 billion in 2021 to $17.75 billion in 2022 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The prostate cancer drugs market is expected to grow to $22.98 billion in 2026 at a CAGR of 6.7%. The increasing male geriatric population is a major driver for the prostate cancer drugs market. Prostate cancer is one of the most common types of cancer in men aged above 60. According to the United Nations (UN), there were around 703 million people aged 65 or above globally, accounting for 13% of the global population in 2019. The American Cancer Society's statistics for prostate cancer in the USA state that about 6 prostate cancer cases in 10 are diagnosed in men aged 65 or above, and it is rare for men aged less than 40. Recurrent/non-responsive prostate cancer is a major restraint for the growth of the prostate cancer drugs market. This is because recurrent/non-responsive prostate cancer cells lead to recurrence or spread of cancer after initial treatment. Prostate cancer can recur locally in the tissue next to the prostate, the surrounding lymph nodes in the pelvis or lymph nodes outside this area, tissues next to the prostate (such as the muscles that help control urination, the rectum, or the wall of the pelvis). Cancer can also travel through the bloodstream and recur in bones or other organs. According to the American Society of Clinical Oncology (ASCO), around 50% to 95% of men in the US with high-risk prostate cancer experience recurrence after localized treatment. The use of combination therapy to treat prostate cancer is an emerging trend in the market. This is mainly because, in some cases of prostate cancer, monotherapy has not been effective for the patients. In this regard, companies in the prostate cancer drugs market are investing more in combination therapy for the treatment of prostate cancer. For example, Pfizer announced the results of its Phase 3 PROSPER trial in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC), which show that the use of XTANDI (enzalutamide) in combination with androgen deprivation therapy (ADT) significantly reduced the risk of developing metastases or death by 71% compared to using ADT alone. Similarly, other combination therapies such as a combination of radiation therapy and androgen deprivation therapy for men with recurrent prostate cancer, and using chemotherapy drug docetaxel (Taxotere) along with ADT are also being used to treat prostate cancer. The prostate cancer drugs market in the USA is regulated by the FDA which is responsible for the approval of new drugs and lays down regulations related to the treatment of prostate cancer. For instance, the FDA approved Erleada (apalutamide) for the treatment of prostate cancer that has not spread (non-metastatic) but continues to grow despite treatment with hormone therapy (castration-resistant). This was the first case of FDA-approved treatment for non-metastatic, castration-resistant prostate cancer, and more such approvals are expected to follow in the future. Hence, the regulatory scenario related to prostate cancer drugs will encourage more drug manufacturers to enter the market. In June 2021, Bayer, a Germany-based pharmaceutics company acquired Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc for an undisclosed amount. With this acquisition, Bayer will gain exclusive access to a specialized alpha radionuclide investigational drug built on actinium-225 and a small molecule aimed against prostate-specific membrane antigen. PSMA Therapeutics Inc. is a US-based company that specializes in prostate-specific membrane antigen research and Noria Therapeutics Inc. is a radiotherapy firm focused on creating alpha-emitting radiopharmaceuticals for targeted therapeutic and imaging applications in oncology. Major players in the prostate cancer drugs market are Astellas Inc., AstraZeneca plc, Johnson & Johnson, Sanofi S.A, Bayer AG, Roche, Abbott, Pfizer, Norvaris and F. Hoffmann-La Roche AG. North America is the largest region in the prostate cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prostate cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global prostate cancer drugs market is segmented - 1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer 2) By Therapy: Hormonal Therapy, Chemotherapy , Immunotherapy, Targeted Therapy 3) By End User: Hospitals, Clinics, Others

The skin cancer drugs market consists of sales of skin cancer drugs. Skin Cancer is an unrestricted growth of abnormal skin cells that lead skin cells to proliferate rapidly and form malignant tumors. Skin cancer can be of various types including actinic keratoses, basal cell carcinoma, squamous cell carcinoma, or melanoma. Examples of skin cancer drugs include 5-FU, Aldara, and Efudex. The main types of skin cancer drugs are actinic keratoses (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma. Actinic keratoses are broad, rough skin patches that can turn cancerous. It commonly appears on sun-exposed regions such as the face, scalp, backs of the hands, and chest. It is especially common in fair-skinned persons. Solar keratosis and senile keratosis are two terms for the same condition. The different classes of drugs include chemotherapy, immunotherapy, targeted agents & other drugs and are used in various sectors such as hospitals, cancer research centers, and clinics. The skin cancer drugs market research report is one of a series of new reports from The Business Research Company that provides skin cancer drugs market statistics, including skin cancer drugs industry global market size, regional shares, competitors with a skin cancer drugs market share, detailed skin cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the skin cancer drugs industry. This skin cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global skin cancer drugs market grew from $2.61 billion in 2021 to $3.07 billion in 2022 at a compound annual growth rate (CAGR) of 17.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, effecting many markets across the globe. The global skin cancer drugs market is expected to grow to $5.01 billion in 2026 at a CAGR of 13.1%.. A significant rise in the prevalence of skin cancer is driving the demand for drugs for Skin Cancer. To treat such high cases of skin cancer, more new innovative skin cancer drugs are being manufactured. According to the American Academy Of Dermatology, in 2019, there were 192,310 new cases of Melanoma type skin cancer. Additionally, the non-invasive type of skin cancer count could rise to 95,830 and 96,480 invasive skin cancer could be diagnosed in the US in 2019. According to the American Academy Of Dermatology, each year roughly 3 million Americans get diagnosed with skin cancer. This is boosting the demand for skin cancer drugs and thus driving the market. The increasing use of biologics and targeted therapies is acting as a restraint in the skin cancer drugs market. The targeted therapies drugs target melanoma cells only. The chemical drugs attack any fast-dividing cells while targeted therapies only attack the skin cancer-causing melanoma cells. Thus, doctors are preferring targeted therapies to treat skin cancer. This is expected to affect the sales of conventional chemical skin cancer drugs and limit the growth of the market going forward. Companies in the Skin Cancer Market are increasingly looking for Strategic Alliances with other companies in the market. Strategic Alliance would help companies to enhance their R&D capability, expedite the development process of new drugs, and reinforce their competitive position in the market. For example, Leo Pharma has formed a strategic alliance with PellePharm, to develop a drug to treat a very rare form of skin cancer called Gorlin syndrome. MorphoSys and LEO Pharma strategically worked together to develop antibodies for the treatment of skin cancer. Pfizer had entered into a strategic alliance with Merck KGaA to manufacture an innovative drug for skin cancer. The European Medicines Agency (EMA) is the regulatory body that evaluates and supervises the production and sales of medicines for the safety and benefit of the customer, in the European Union Region. The manufacturers of skin cancer drugs and all other drugs need to comply with manufacturing practices specified by the EMA. EMA also regulates and supervises the drug quality, checking for the intended use of the drug and whether the drug is meeting the requirement of a clinical trial. EMA also educates the patients regarding the risks associated with taking skin cancer drugs such as Tafinlar and Opdivo, what are the safety measures that are needed to be taken while consuming the drug, the benefits of the drug, and all other relevant information about such drugs. In April 2019, Bristol-Myers Squibb acquired Celgene for $74 billion. This acquisition would help Bristol-Myers Squibb to widen its portfolio of the drugs in skin cancer market. This acquisition would also help Bristol-Myers Squibb to expedite the development of new innovative drugs which are in the early stages of the drug pipeline. Celgene is an innovative biotechnology company that manufactures and develops cancer drugs. Celgene was founded in 1986 and is headquartered in Summit, New Jersey, United States. Major players in the skin cancer drugs market are Novartis AG, Bristol Myers Squibb, Eli Lilly, Meda, Sun Pharmaceutical Industries Ltd, Roche, Aqua Pharmaceuticals, Bausch Health, GlaxoSmithKline PLC and Pfizer Inc. North America is the largest region in the skin cancer drugs market in 2021. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the skin cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the skin cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global skin cancer drugs market is segmented - 1) By Type: Actinic Keratoses (AK), Basal cell carcinoma (BCC), Squamous cell carcinoma (SCC), Melanoma 2) By End Users: Hospitals, Cancer Research Centers, Clinics 3) By Drug Class: Chemotherapy, Immunotherapy, Targeted Agents & Other Drugs

The viral vectors & plasmid DNA market consists of sales of viral vectors & plasmid DNA and related services. The viral vectors & plasmid DNA are used for the delivery of cellular therapies, like gene therapy and immunotherapy, and also for treating some viral infections. The viral vectors & plasmid DNA are used for formulation development in research and development labs. The viral vectors are genetically engineered viruses carrying viral RNA or DNA that is non-infectious but still contain viral promoters and transgene. The plasmid DNA is a double-stranded extrachromosomal and circular DNA sequence that is capable of replication using the host cell's replication system. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical, and pharmaceutical companies. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global viral vectors & plasmid DNA market is expected to grow from $0.69 billion in 2021 to $0.80 billion in 2022 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The viral vectors & plasmid DNA market is expected to reach $1.38 billion in 2026 at a CAGR of 14.8%. The rise in the global incidence of cancer is driving the viral vector & plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States. Furthermore, according to the American Cancer Society, in 2019, around 606,880 deaths were caused in the USA due to prevalence of the cancer. Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. The unaffordable cost of gene therapies is a major challenge in the viral vectors & plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. In January 2020, Cognate Bioservices Inc, a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialized in providing manufacturing services for plasmid DNA and viral vector, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. North America is the largest region in the iral vectors & plasmid DNA market in 2021. Middle East is expected to be the fastest growing region. The regions covered in the iral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Others 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Others 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

The bi-specific MAbs or bispecific monoclonal antibodies market consists of sales of bispecific monoclonal antibodies and related services. Bi-Specific MAbs are artificial proteins that can bind two or more antigens into a single product. Bispecific monoclonal antibodies are used to improve immune response in various medical conditions and find their applications in the field of drug delivery and cancer immunotherapy. The main types of bi-specific are catumaxomab (removal), blinatumomab, duligotumab, and SAR 156597. Catumaxomab is a rat-mouse hybrid monoclonal antibody used to treat malignant ascites, a condition that occurs in people who have metastasizing cancer. The various product types including in vivo, and in vitro are used for the treatment of cancer, autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, and others. The bispecific monoclonal antibodies are used by hospitals, research institutes, and others. The bi-specific MAbs or bispecific monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides bi-specific MAbs or bispecific monoclonal antibodies market statistics, including bi-specific MAbs or bispecific monoclonal antibodies industry global market size, regional shares, competitors with a bi-specific MAbs or bispecific monoclonal antibodies market share, detailed bi-specific MAbs or bispecific monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the bi-specific MAbs or bispecific monoclonal antibodies industry. This bi-specific MAbs or bispecific monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global bi-specific mabs market is expected to grow from $3.80 billion in 2021 to $5.13 billion in 2022 at a compound annual growth rate (CAGR) of 34.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The bi-specific MAbs or bispecific monoclonal antibodies market is expected to reach $11.64 billion in 2026 at a CAGR of 22.7%. The increasing prevalence of cancer and other chronic diseases is projected to contribute to the growth of the bispecific monoclonal antibodies market over the forecast period. Bispecific monoclonal antibodies are developed for the treatment of various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders. Bispecific monoclonal antibodies are considered to be more effective than monoclonal antibodies (moAbs) as these target two or more tumor antigens on cells to disrupt cancer progression. According to the World Health Organization, cancer is the leading cause of death worldwide and is responsible for around 10 million deaths in 2020. Additionally, according to the Centers for Disease Control and Prevention, chronic diseases are among the most prevalent diseases with 6 out of 10 adults suffering from at least one chronic disease in the USA. Therefore, a rising number of chronic diseases including cancer is anticipated to propel the demand for bi-specific MAbs market to treat these diseases effectively. The availability of various alternative treatment methods for cancer is expected to limit the growth of the bispecific monoclonal antibodies market. Alternative cancer treatment therapies and methods used for the treatment of cancer including dietary treatments, acupuncture, homeopathy, and herbal remedies are gaining popularity in recent years attributed to side effects of chemotherapeutic anticancer agents. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many of the herbs used in Ayurveda have anti-cancer properties, for example, andrographis paniculata. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes. Therefore, this affects the biologic sales and hence impacts the bi-specific MAbS market. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027, growing at a CAGR of 14% during the forecast period. The less expensive alternative medicines increase competition for the biologics market, thereby, hindering the growth of the bi-specific MAbs market shortly. Companies in the bi-specific MAbS market are increasingly investing in various strategic initiatives such as collaborations and partnerships to expand the product portfolio and geographical presence of the company. For instance, in June 2020, AbbVie Inc., a US-based biopharmaceutical company entered into a collaboration agreement with Genmab A/S, a Danish biotechnology company, to develop and commercialize antibody therapeutics for cancer treatment. The companies together will work on three early-stage bispecific antibody candidates of Genmab A/S including DuoHexaBody-CD37, epcoritamab, and DuoBody-CD3x5T4 along with discovering new antibody therapeutics. Moreover, in July 2020, Atreca, Inc., a US-based clinical-stage biotechnology company, and Xencor, Inc. entered into a strategic partnership to develop, discover, and commercialize Novel T cell engaging bispecific antibodies as potential therapeutics for oncology treatment. Xencor, Inc. is a US-based biopharmaceutical company developing engineered monoclonal antibodies for cancer and autoimmune disease treatment. In August 2020, AbCellera, a biotechnology firm based in Canada, completed the acquisition of the OrthoMab bispecific platform from Dualogics for an undisclosed amount. The acquisition integrated OrthoMab into AbCellera’s existing technology stack, which provided the industry with a rapid and complete solution for generating tailored, stable, and developable bispecific antibodies Dualogics is a US-based biotechnology company specialized in protein engineering for improving antibody therapeutics. Major players in the bi-specific MAbs or bispecific monoclonal antibodies market are Johnson & Johnson, Novartis AG, Hoffmann-La Roche Ltd., Novo Nordisk A/S, Bayer AG, Thermo Fisher Scientific, Inc., Bistro-Myers Squibb. Mylan N.V., Daiichi Sankyo Company Ltd. and Abbott. The regions covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the bi-specific MAbs or bispecific monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The global bi-specific mabs market is segmented - 1)By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, SAR 156597 2)By Product Type: In Vivo, In Vitro 3)By Indication: Cancer, Autoimmune Diseases, Inflammatory Diseases, Infectious Diseases, Microbial Diseases, Others 4)By End Use: Hospitals, Research Institutes, Others,